Proqr Therapeutics (PRQR)

Trade PRQR now with
3/24/2021 7:21:38 AM ProQR Therapeutics Announces Positive Results From Phase 1/2 Stellar Trial Of QR-421a In Usher Syndrome
3/17/2021 7:08:52 AM ProQR To Present And Discuss Results From Its Phase 1/2 Stellar Trial Of QR-421a
10/5/2020 7:12:48 AM ProQR Appoints Naveed Shams As Chief Scientific Officer
3/31/2020 6:10:39 AM ProQR Announces Positive Findings From Interim Analysis In Phase 1/2 Trial Of QR-421a For Usher Syndrome
10/15/2014 12:34:54 PM Deutsche Bank Initiates ProQR Therapeutics (PRQR) At Buy With $32 Price Target